View Older Stories View More Recent Stories
-
Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines
-
Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multip
-
AavantiBio Announces Formation of Scientific Advisory Board
-
Ventus Therapeutics Closes $140 Million Series C Financing
-
Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders
-
Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform
-
PepGen Appoints Laurie Keating as Chair of Board of Directors
-
TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer
-
TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer
-
Form SC 13G PARDES BIOSCIENCES, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
-
Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
-
Hemab Therapeutics Appoints John Maraganore as Chair of Board of Directors and Welcomes New Additions to Board and Leadership Team
-
AavantiBio to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19
-
Form SC 13G BELLUS Health Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G RELMADA THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Tasso Secures $100M in Series B Financing
-
Nodexus Inc. Emerges from Stealth with $30 Million Series A Funding to Advance Manufacturing and Expand Commercialization of NX One Platform
-
Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma
-
PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations
-
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
-
Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC
-
Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC
-
NanoMosaic Closes a $40.75MM Over-Subscribed Series A Round
-
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
-
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
-
Form SC 13G IO Biotech, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer
-
Form SC 13G/A ARYA Sciences Acquisitio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Trillium Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Aadi Bioscience, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G LianBio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
-
Form SC 13G/A Helix Acquisition Corp Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A CURIS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Inozyme Pharma, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ARDELYX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data
-
Form SC 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline
-
Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline
-
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
-
PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development
-
Alcon (ALC) to Acquire Ivantis for $475M Upfront
-
Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio
-
Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio
-
Form SC 13G Xilio Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Concert Pharma (CNCE) Announces $65M Institutional Financing
-
Concert Pharmaceuticals Announces $65 Million Financing
